Preemptive Resuscitation for Eradication of Septic Shock
The purpose of this study is to assess the ability of an empiric resuscitation strategy compared to standard care to decrease the incidence of organ failure in normotensive sepsis patients.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Preemptive Empiric Resuscitation Protocol for the Prevention of Disease Progression in the Treatment of Sepsis|
- Organ failure [ Time Frame: 72 hours ] [ Designated as safety issue: No ]Development of worsening organ failure (SOFA score increased by >1 point) over 72 hours.
- Mortality [ Time Frame: In-hospital ] [ Designated as safety issue: No ]All-cause in-hospital mortality (up to 1 year).
- Volume overload [ Time Frame: 12 hours following treatment initiation ] [ Designated as safety issue: Yes ]
Composite safety endpoint:
- Premature termination of the protocol-directed intravenous fluid administration by the investigator or primary physician due to presumed volume overload
- Administration of intravenous diuretic for acute pulmonary edema
- Respiratory failure requiring ventilatory assistance (BiPAP, CPAP, or mechanical ventilation) secondary to pulmonary edema per primary care team
|Study Start Date:||September 2011|
|Estimated Study Completion Date:||March 2015|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
No Intervention: Control
Standard medical care by the primary treatment team.
Experimental: Interventional arm
Protocolized empiric resuscitation.
Drug: Intravenous fluid
0.9% Sodium chloride intravenous fluid
Other Name: Normal saline
Sepsis is a challenging and elusive entity with a high mortality rate. As a syndrome, clinicians are challenged to distinguish individuals with systemic infection warranting further interventions from lower severity patients. Sepsis is now recognized as a time-sensitive emergency, as patients stand the best chance for survival when effective therapeutic interventions are delivered as early as possible.
Recent data has shown that in-hospital disease progression from sepsis to septic shock is associated with a higher risk of morbidity and mortality than those with shock on initial presentation. Yet, even when identified and treated with early aggressive interventions, the development of septic shock is still associated with a mortality rate of 25-40%.
Although the presence of sustained arterial hypotension or serum lactate elevation (>4.0 mmol/L) are the currently recommended threshold to define the presence of overt shock and the need for aggressive resuscitation, the investigators have shown that, in patients with systemic infection, a moderate lactate elevation (2.0-3.9 mmol/L) is a common occurrence and an important warning sign for the increased risk of disease progression and death. Sepsis with an elevated lactate between 2.0-3.9, referred to as the "PRE-SHOCK" state, identifies this population of patients at-risk for poor outcome. Current guidelines for sepsis management do not recommend any specific resuscitation measures or therapies for this at-risk population. This study marks the first in a series of investigations addressing the PRE-SHOCK population to further define the adverse events within this cohort and to investigate novel interventions to improve outcomes.
The investigators hypothesize that an early quantitative resuscitation strategy using a protocol-directed IV fluid resuscitation will result in a significant reduction in the development of worsening organ failure (including shock) and mortality compared to standard care.
|Contact: Ryan C Arnold, MDemail@example.com|
|Contact: Alan Jones, MDfirstname.lastname@example.org|
|United States, Delaware|
|Christiana Care Health System||Recruiting|
|Newark, Delaware, United States, 19718|
|Contact: Ryan Arnold, MD 302-304-1828 email@example.com|
|Contact: Debra Marco, RN 302-733-4130 DMarco@Christianacare.org|
|Principal Investigator: Ryan C Arnold, MD|
|United States, Massachusetts|
|Beth Israel Deaconess Medical Center||Recruiting|
|Boston, Massachusetts, United States, 02215|
|Contact: Nathan I Shapiro, MD, MPH firstname.lastname@example.org|
|Principal Investigator: Nathan I Shapiro, MD, MPH|
|United States, Michigan|
|Detroit Receiving Hospital/University Health Center||Recruiting|
|Detroit, Michigan, United States, 48201|
|Contact: Robert L Sherwin, MD RSherwin@dmc.org|
|Principal Investigator: Robert Sherwin, MD|
|Sub-Investigator: James Paxton, MD, MBA|
|United States, Mississippi|
|University of Mississippi Medical Center||Recruiting|
|Jackson, Mississippi, United States, 39216|
|Contact: Sarah Sterling 601-984-5782 email@example.com|
|Contact: Alan Jones, MD firstname.lastname@example.org|
|Sub-Investigator: Alan Jones, MD|
|Principal Investigator: Sarah A Sterling, MD|
|United States, New Jersey|
|Cooper University Hospital:Cooper Medical School of Rowan University||Completed|
|Camden, New Jersey, United States, 08103|
|Study Chair:||Alan Jones, MD||University of Mississippi Medical Center|
|Principal Investigator:||Ryan Arnold, MD||Cooper University Hospital: Cooper Medical School of Rowan University|